Acasti Pharma Q3 FY2024 net loss narrows to $2.4M; cash runway extends to early 2026

Grace Therapeutics, Inc.

2024-Q3 EPS reported -$1.09

Net loss of $2.4M ($0.21/share) vs $3.9M ($0.52) in prior-year quarter.
R&D expenses decreased 44% YoY to $1.4M due to resource prioritization on GTX-104.
Cash, equivalents and ST investments $25.1M; runway extended into 2nd calendar Q 2026.
Pivotal STRIVE-ON Phase 3 trial enrollment ongoing; NDA submission on track for 1H 2025.
Company secured $7.5M private placement in prior quarter to bolster balance sheet.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Grace Therapeutics, Inc. reported the quarter ended December 31, 2023 results: net income $2.4 million, EPS $0.21 per share.

Period: the quarter ended December 31, 2023
Net income: $2.4 million
EPS: $0.21 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $2.4 million, or $0.21 per share, for the three months ended December 31, 2023

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Grace Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-013568

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.